Biomarkers and Susceptibility Unit, and Biomedical Research Center Network for Epidemiology and Public Health, Cancer Prevention and Control Program, Catalan Institute of Oncology, Bellvitge Institute for Biomedical Research (IDIBELL), Gran Via 199, L'Hospitalet, Barcelona 08908, Spain.
Breast Cancer Res Treat. 2011 Oct;129(3):947-54. doi: 10.1007/s10549-011-1546-7. Epub 2011 May 4.
Intracellular signaling mediated by the receptor activator of nuclear factor-κB [Rank, encoded by the tumor necrosis factor receptor superfamily, member 11a (Tnfrsf11a) gene] is fundamental for mammary gland development in mice, regulating the expansion of stem and progenitor cell compartments. Conversely, Rank overexpression in mice promotes abnormal proliferation and impairs differentiation, leading to an increased incidence of tumorigenesis. Here, we show that a common genetic variant near the 5'-end of TNFRSF11A, rs7226991, is associated with breast cancer risk in the general population and among carriers of mutations in the breast cancer 2, early onset (BRCA2) gene. Akin to the results of the Cancer and Genetics Markers of Susceptibility initiative, combined analysis of rs7226991 in two Spanish case-control studies (1,365 controls and 1,323 cases in total) revealed a significant association with risk: odds ratio (OR) = 0.88, 95% confidence interval (CI) 0.78-0.98, P (trend) = 0.025. Subsequent examination of BRCA1 (n = 1,017) and BRCA2 (n = 885) mutation carriers revealed a consistent association in the latter group: weighted hazard ratio ((w)HR) = 0.70; 95% CI 0.55-0.88; and P (trend) = 0.003; compared to BRCA1 mutation carriers, (w)HR = 0.91; 95% CI 0.76-1.10; and P (trend) = 0.33. The results of this study need to be replicated in other populations and with larger numbers of BRCA1/2 mutation carriers.
核因子-κB 受体激活剂[Rank,由肿瘤坏死因子受体超家族成员 11a(Tnfrsf11a)基因编码]介导的细胞内信号对于小鼠乳腺发育至关重要,调节干细胞和祖细胞区室的扩张。相反,Rank 在小鼠中的过度表达促进异常增殖并损害分化,导致肿瘤发生的发生率增加。在这里,我们表明 TNFRSF11A 基因 5'端附近的一个常见遗传变异 rs7226991 与普通人群和乳腺癌 2 基因(BRCA2)突变携带者的乳腺癌风险相关。与癌症和遗传标记易感性倡议的结果相似,对两个西班牙病例对照研究(共 1365 名对照和 1323 名病例)中 rs7226991 的联合分析显示与风险显著相关:优势比(OR)=0.88,95%置信区间(CI)0.78-0.98,P(趋势)=0.025。随后对 BRCA1(n=1017)和 BRCA2(n=885)突变携带者的检查显示在后一组中存在一致的关联:加权风险比((w)HR)=0.70;95%CI 0.55-0.88;和 P(趋势)=0.003;与 BRCA1 突变携带者相比,(w)HR=0.91;95%CI 0.76-1.10;和 P(趋势)=0.33。该研究的结果需要在其他人群和更多 BRCA1/2 突变携带者中进行复制。